Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A.

Cancer Res. 2007 Mar 15;67(6):2643-8.

2.

[The RAS paradox of the EGFR-targeted therapy in colorectal cancer].

Tímár J, Láng I.

Magy Onkol. 2008 Jun;52(2):185-91. doi: 10.1556/MOnkol.52.2008.2.7. Review. Hungarian.

PMID:
18640895
3.

KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue.

Silvestris N, Tommasi S, Santini D, Russo A, Simone G, Petriella D, Maiello E, Tonini G, Colucci G.

Expert Opin Biol Ther. 2009 May;9(5):565-77. doi: 10.1517/14712590902870394 . Review.

PMID:
19368524
4.

[Anti-EGFR antibody therapy for colorectal cancer].

Ishikawa T, Uetake H, Sugihara K.

Nihon Rinsho. 2012 Dec;70(12):2152-8. Review. Japanese.

PMID:
23259389
5.

Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK.

Martinelli E, Morgillo F, Troiani T, Ciardiello F.

Cancer Treat Rev. 2017 Feb;53:61-69. doi: 10.1016/j.ctrv.2016.12.001. Epub 2016 Dec 30. Review.

PMID:
28073102
6.

[Predictive factors of response to anti-EGFR treatments in colorectal cancer].

Lièvre A, Laurent-Puig P.

Bull Cancer. 2008 Jan;95(1):133-40. doi: 10.1684/bdc.2008.0551. Review. French.

7.

Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.

Troiani T, Zappavigna S, Martinelli E, Addeo SR, Stiuso P, Ciardiello F, Caraglia M.

Expert Opin Biol Ther. 2013 Feb;13(2):241-55. doi: 10.1517/14712598.2012.756469. Epub 2013 Jan 3. Review.

PMID:
23281932
8.

Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer.

Chua W, Moore MM, Charles KA, Clarke SJ.

Curr Opin Mol Ther. 2009 Dec;11(6):611-22. Review.

PMID:
20072938
9.

Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer.

Jeong WJ, Cha PH, Choi KY.

World J Gastroenterol. 2014 Aug 7;20(29):9862-71. doi: 10.3748/wjg.v20.i29.9862. Review.

10.

Acquired resistance to EGFR-targeted therapies in colorectal cancer.

Van Emburgh BO, Sartore-Bianchi A, Di Nicolantonio F, Siena S, Bardelli A.

Mol Oncol. 2014 Sep 12;8(6):1084-94. doi: 10.1016/j.molonc.2014.05.003. Epub 2014 May 14. Review.

11.

Oncogenic mutations as predictive factors in colorectal cancer.

Lièvre A, Blons H, Laurent-Puig P.

Oncogene. 2010 May 27;29(21):3033-43. doi: 10.1038/onc.2010.89. Epub 2010 Apr 12. Review.

PMID:
20383189
12.

Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer.

Okada Y, Miyamoto H, Goji T, Takayama T.

Digestion. 2014;89(1):18-23. doi: 10.1159/000356202. Epub 2014 Jan 20. Review.

13.

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.

Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, Papadimitriou CA, Murray S.

Lancet Oncol. 2008 Oct;9(10):962-72. doi: 10.1016/S1470-2045(08)70206-7. Epub 2008 Sep 17. Review.

PMID:
18804418
14.

Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.

Vokes EE, Chu E.

Oncology (Williston Park). 2006 Apr;20(5 Suppl 2):15-25. Review.

PMID:
16736979
15.

Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies.

Gialeli Ch, Kletsas D, Mavroudis D, Kalofonos HP, Tzanakakis GN, Karamanos NK.

Curr Med Chem. 2009;16(29):3797-804. Review.

PMID:
19747140
16.

Epidermal growth factor receptor as a therapeutic target in colorectal cancer.

Cohen RB.

Clin Colorectal Cancer. 2003 Feb;2(4):246-51. Review.

PMID:
12620146
17.

Role of anti-EGFR target therapy in colorectal carcinoma.

Enrique AA, Gema PC, Jeronimo JC, Auxiliadora GE.

Front Biosci (Elite Ed). 2012 Jan 1;4:12-22. Review.

PMID:
22201852
18.

EGFR-ras-raf signaling in epidermal stem cells: roles in hair follicle development, regeneration, tissue remodeling and epidermal cancers.

Doma E, Rupp C, Baccarini M.

Int J Mol Sci. 2013 Sep 25;14(10):19361-84. doi: 10.3390/ijms141019361. Review.

19.

Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer.

Luo HY, Xu RH.

World J Gastroenterol. 2014 Apr 14;20(14):3858-74. doi: 10.3748/wjg.v20.i14.3858. Review.

20.

RAS and BRAF in metastatic colorectal cancer management.

Gong J, Cho M, Fakih M.

J Gastrointest Oncol. 2016 Oct;7(5):687-704. Review.

Supplemental Content

Support Center